NYSE:RCUS Arcus Biosciences Q2 2025 Earnings Report $11.50 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$11.40 -0.10 (-0.83%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Arcus Biosciences EPS ResultsActual EPS-$1.11Consensus EPS -$1.14Beat/MissBeat by +$0.03One Year Ago EPS-$1.02Arcus Biosciences Revenue ResultsActual Revenue$160.00 millionExpected Revenue$32.86 millionBeat/MissBeat by +$127.14 millionYoY Revenue Growth+310.30%Arcus Biosciences Announcement DetailsQuarterQ2 2025Date8/6/2025TimeAfter Market ClosesConference Call DateWednesday, August 6, 2025Conference Call Time4:05PM ETUpcoming EarningsArcus Biosciences' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arcus Biosciences Earnings HeadlinesArcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 12:10 PM | seekingalpha.comBrokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $21.14September 9 at 2:29 AM | americanbankingnews.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.September 12 at 2:00 AM | Banyan Hill Publishing (Ad)Arcus Biosciences Announces New Employment Inducement GrantsSeptember 8, 2025 | businesswire.comThese 3 “Strong Buy” Value Stocks Have over 10% Upside, According to Analysts – 9/3/2025September 3, 2025 | msn.comArcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells. The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody. Additional pipeline assets explore dual checkpoint blockade and next-generation immune modulators. Arcus conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic institutions and global partners to advance its oncology portfolio. Founded in 2015 and headquartered in Redwood City, California, Arcus completed its initial public offering on the New York Stock Exchange in June 2020 under the ticker RCUS. The company has since forged strategic alliances with leading biopharmaceutical firms to accelerate clinical development and broaden the potential application of its immuno-oncology therapeutics. Arcus is led by President and Chief Executive Officer Terry Rosen, who co-founded the company and brings extensive experience in biotech leadership and oncology drug development. The senior management team combines expertise in translational medicine, clinical operations and commercial strategy to guide Arcus toward its goal of delivering new treatment options for patients with cancer.View Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
